These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18308673)

  • 1. The rosigliazone meta-analysis: lessons for the future.
    Shuster JJ; Schatz DA
    Diabetes Care; 2008 Mar; 31(3):e10. PubMed ID: 18308673
    [No Abstract]   [Full Text] [Related]  

  • 2. Faster publication isn't always better.
    Fuster V; Farkouh ME
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
    [No Abstract]   [Full Text] [Related]  

  • 3. Revisiting the rosiglitazone story--lessons learned.
    Rosen CJ
    N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
    [No Abstract]   [Full Text] [Related]  

  • 4. The rosiglitazone meta-analysis.
    McCullough PA; Lepor NE
    Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
    [No Abstract]   [Full Text] [Related]  

  • 5. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
    Misbin RI
    Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
    [No Abstract]   [Full Text] [Related]  

  • 6. [Rosiglitazone--statistics for benefits and problems].
    Hjelmesaeth J; Røislien J
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2702-3. PubMed ID: 17952157
    [No Abstract]   [Full Text] [Related]  

  • 7. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
    Rosen CJ
    N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
    [No Abstract]   [Full Text] [Related]  

  • 8. The Avandia debate: an unhappy conclusion.
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
    [No Abstract]   [Full Text] [Related]  

  • 9. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
    Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
    Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
    Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value equation for rosiglitazone and pioglitazone in older persons.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
    [No Abstract]   [Full Text] [Related]  

  • 12. The rosiglitazone controversy: the Indian perspective.
    Mohan V; Joshi SR
    J Assoc Physicians India; 2007 Jul; 55():477-80. PubMed ID: 17907495
    [No Abstract]   [Full Text] [Related]  

  • 13. Diabetes drug safety update: Avandia and your heart.
    Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
    [No Abstract]   [Full Text] [Related]  

  • 14. Analytical issues regarding rosiglitazone meta-analysis.
    Claggett B; Wei LJ
    Arch Intern Med; 2011 Jan; 171(2):179-80; author reply 180. PubMed ID: 21263111
    [No Abstract]   [Full Text] [Related]  

  • 15. Thiazolidinediones, deadly sins, surrogates, and elephants.
    Cleland JG; Atkin SL
    Lancet; 2007 Sep; 370(9593):1103-4. PubMed ID: 17905146
    [No Abstract]   [Full Text] [Related]  

  • 16. Rosiglitazone, marketing, and medical science.
    Moynihan R
    BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
    [No Abstract]   [Full Text] [Related]  

  • 17. Setting the RECORD Straight.
    Nissen SE
    JAMA; 2010 Mar; 303(12):1194-5. PubMed ID: 20332408
    [No Abstract]   [Full Text] [Related]  

  • 18. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis?
    Bilous RW
    Diabet Med; 2007 Sep; 24(9):931-3. PubMed ID: 17725705
    [No Abstract]   [Full Text] [Related]  

  • 20. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.